H.M. BERGSTEN VENTURES

Investing in the Future of MedTech

We are a highly experienced investment firm with a dedicated focus on innovative MedTech startups. Our mission is to identify and support groundbreaking technologies with the potential to transform the healthcare industry, improve patient outcomes, and provide more effective treatments and diagnostics. By partnering with ambitious entrepreneurs and visionary researchers, we help bring disruptive medical technologies to market, ensuring that cutting-edge innovations reach the patients and healthcare professionals who need them most.

A Portfolio of Game-Changing MedTech Companies

Our portfolio consists of pioneering companies reshaping the medical and healthcare landscape through innovative technologies and solutions. These organizations specialize in cutting-edge developments across diagnostics, imaging, digital health, and therapeutic advancements.

• AI Medical Technology, a company in our portfolio, focuses on AI-powered dermatology tools. These enable more accurate and timely skin cancer diagnoses, improving patient care and reducing diagnostic errors.

• Another company, AMRA Medical, is revolutionizing body composition analysis with MRI-based technology. They provide precise insights into fat and muscle distribution to enhance healthcare decision-making.

• In the realm of oncology, our portfolio includes BioReperia, helps every cancer patient to get the most effective treatment available, for tumor regression and metastasis inhibition in only 5 days.

• Another oncology innovator, Celluminova, is developing new tools for stem cell research, including cancer stem cells.

• We have invested in Evam, a leading global supplier of mission-critical mobile data solutions for Police, Ambulance, Fire & Rescue, and other Public Safety Organizations.

• Our portfolio also encompasses digital health innovator MediTuner, specializing in respiratory care. They empower patients with tools to monitor lung function remotely, facilitating proactive treatment.

• Additionally, we have invested in VOC Diagnostics, a company developing a unique detection method by analyzing volatile organic compounds from blood plasma samples to detect ovarian cancer with higher accuracy than any other available method.

• Finally, we have invested in Worldish, a communication technology company that provides AI-powered medical translation and language learning tools to break down language barriers in healthcare.

By supporting these forward-thinking ventures, our portfolio drives progress in medical technology, bringing transformative solutions to healthcare providers and patients worldwide.

Our Founder

Our firm was founded by Mikael Bergsten, a highly accomplished investor and healthcare industry expert. As a former partner at EY and a PhD researcher educated at Harvard Business School, Mikael brings a unique combination of financial expertise, strategic insight, and deep industry knowledge. His extensive experience in investment strategy, corporate finance, and MedTech innovation has been instrumental in shaping our approach to identifying and nurturing high-potential startups.

We Are Proud of the Work We Do

We take immense pride in the work we do and the impact we make on global health. Our investments go beyond generating returns; they are about making a lasting difference in people’s lives. From supporting breakthrough medical devices that enhance surgical precision to funding AI-driven diagnostic tools that improve early disease detection, we are actively contributing to the future of healthcare. As part of our values, we also make financial donations to the Swedish Cancer Society and Swedish Heart Lung Foundation to support their vital work in funding cancer and heart-lung research in Sweden.